FINWIRES · TerminalLIVE
FINWIRES

TPE:6838

4 stories mentioning TPE:6838Updated 4h ago

Every FINWIRES story that references TPE:6838, newest first.

Asia

Formosa Pharmaceuticals Partner Applied for Drug Review to Australian Drug Authority

Formosa Pharmaceuticals (TPE:6838) said its authorized partner, Arrotex Pharmaceuticals, has applied to the Therapeutic Goods Administration (TGA) of Australia for the drug inspection registration and review of the drug APP13007, according to a Friday filing to the Taiwan stock exchange.The company's shares were down nearly 1% in Monday's trade.The drug is intended for the treatment of inflammation and pain after eye surgery.Arrotex Pharmaceuticals will bear all the costs associated with the application for drug inspection and registration.

TPE:6838
Asia

Formosa Pharmaceuticals, Samil Pharmaceutical Sign Drug Licensing Deal in Vietnam

Formosa Pharmaceuticals (TPE:6838) signed an exclusive licensing deal with South Korea's Samil Pharmaceutical (KRX:000520) for commercialization rights of its ophthalmic drug clobetasol propionate suspension (APP13007) in Vietnam.The agreement covers treatment for post-operative eye inflammation and pain, with financial terms including upfront payments, milestones and royalties, according to a Thursday Taiwan Exchange filing.Formosa said the Vietnam eye care market offers steady growth, and the deal is expected to support future sales and business development.Deal details, however, remain confidential.

KRX:000520TPE:6838
Asia

Formosa Pharmaceuticals Gets Taiwan's Health Ministry for Pain Relief Drug; Shares Rise 3%

Formosa Pharmaceuticals (TPE:6838) received approval from Taiwan's Ministry of Health and Welfare for a drug to treat inflammation and pain following ocular surgery, according to a Monday Taiwan Exchange filing.Shares gained about 3% in Tuesday's late morning trade.The drug dubbed APP13007, is marketed as BYQLOVI Ophthalmic Suspension 0.05%.Financial details and accumulated development costs were not disclosed.

TPE:6838
Asia

Formosa Pharmaceuticals' BYQLOVI Eye Drop Wins Taiwan Approval for Post-Surgery Pain Treatment

Taiwan's Ministry of Health and Welfare approved Formosa Pharmaceuticals' (TPE:6838) eye-drop BYQLOVI for post-surgery eye-pain treatment, according to a filing on Tuesday.The new drug, approved Tuesday, has a code of APP13007.

TPE:6838

Track with the FINWIRES app suite

FolioX
FolioX
Track TPE:6838 in your portfolio
WheelAI
WheelAI
Analyze TPE:6838 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on TPE:6838